1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2014

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2014" provides data on the Chemotherapy Induced Peripheral Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Peripheral Neuropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chemotherapy Induced Peripheral Neuropathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Chemotherapy Induced Peripheral Neuropathy 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Chemotherapy Induced Peripheral Neuropathy 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials 30
Prominent Drugs 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Spectrum Pharmaceuticals, Inc. 34
Clinical Trial Overview of Spectrum Pharmaceuticals, Inc. 34
Sigma-Tau S.p.A. 35
Clinical Trial Overview of Sigma-Tau S.p.A. 35
Sanofi 36
Clinical Trial Overview of Sanofi 36
Immune Pharmaceuticals, Inc. 37
Clinical Trial Overview of Immune Pharmaceuticals, Inc. 37
DARA BioSciences, Inc. 38
Clinical Trial Overview of DARA BioSciences, Inc. 38
CK Life Sciences Int'l., (Holdings) Inc. 39
Clinical Trial Overview of CK Life Sciences Int'l., (Holdings) Inc. 39
CeNeRx BioPharma, Inc. 40
Clinical Trial Overview of CeNeRx BioPharma, Inc. 40
Ajanta Pharma Limited 41
Clinical Trial Overview of Ajanta Pharma Limited 41
Clinical Trial Overview of Top Institutes / Government 42
University of Texas M. D. Anderson Cancer Center 42
Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center 42
North Central Cancer Treatment Group 43
Clinical Trial Overview of North Central Cancer Treatment Group 43
Mayo Clinic 44
Clinical Trial Overview of Mayo Clinic 44
Meiwa Hospital 45
Clinical Trial Overview of Meiwa Hospital 45
The Gynecologic Oncology Group 46
Clinical Trial Overview of The Gynecologic Oncology Group 46
Northwestern University 47
Clinical Trial Overview of Northwestern University 47
New Mexico Cancer Care Alliance 48
Clinical Trial Overview of New Mexico Cancer Care Alliance 48
Columbia University 49
Clinical Trial Overview of Columbia University 49
Legacy Health System 50
Clinical Trial Overview of Legacy Health System 50
University of Sao Paulo 51
Clinical Trial Overview of University of Sao Paulo 51
Five Key Clinical Profiles 52
Appendix 127
Abbreviations 127
Definitions 127
Research Methodology 128
Secondary Research 128
About GlobalData 128
Contact Us 128
Disclaimer 129
Source 129

List of Tables
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region, 2014* 8
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Chemotherapy Induced Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 33
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Spectrum Pharmaceuticals, Inc., 2014* 34
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Sigma-Tau S.p.A., 2014* 35
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 36
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Immune Pharmaceuticals, Inc., 2014* 37
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by DARA BioSciences, Inc., 2014* 38
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by CK Life Sciences Int'l., (Holdings) Inc., 2014* 39
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by CeNeRx BioPharma, Inc., 2014* 40
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Ajanta Pharma Limited, 2014* 41
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2014* 42
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 43
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 44
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Meiwa Hospital, 2014* 45
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by The Gynecologic Oncology Group, 2014* 46
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 47
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by New Mexico Cancer Care Alliance, 2014* 48
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014* 49
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by Legacy Health System, 2014* 50
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014* 51

List of Figures
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Peripheral Neuropathy to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Chemotherapy Induced Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Chemotherapy Induced Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Chemotherapy Induced Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 128

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.